Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting

– Six-year natural history comparison with maralixibat demonstrates event-free and transplant-free survival in patients with Alagille syndrome (ALGS)

– Characterization of four-year growth improvement in Alagille syndrome with maralixibat

– New analysis evaluating health-related quality of life impact assessed on caregivers of children with Alagille syndrome

– Mirum to host a scientific symposium on the clinical benefits of treating cholestasis in children

Excerpt from the Press Release:

FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) shared data from three posters presented during the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting (NASPGHAN) taking place October 12-16, 2022, in Orlando, Florida.

“Our presence at NASPGHAN provides an exciting opportunity for Mirum to showcase maralixibat six-year event-free survival benefit over the natural history standard of care, as well as long-term improvements in growth in patients with Alagille syndrome,” said Pam Vig, PhD, head of research and development at Mirum. “Further, while the burden of pruritus on patients with Alagille syndrome has been well-characterized through prior analyses, the impact to caregivers has been underappreciated, from mental health to financial distress.”

Scientific Symposium

The company will also host a scientific symposium: “Beyond Itch: Exploring the Clinical Benefits of Treating Cholestasis in Children,” featuring Drs. William F. Balistreri (chair), Regino P. Gonzalez-Peralta, Binita M. Kamath, and Saeed Mohammad.

The event will take place on Thursday, October 13, 2022, from 7:15-8:45pm ET in Sebastian L 1/2.

Click the button below to read the entire Press Release:

Continue Reading The Press Release